Skip to search formSkip to main contentSkip to account menu

bavituximab

Known as: Chimeric Anti-Phosphotidylserine Monoclonal Antibody 
A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

Tarvacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.
2546 Background: Glioblastoma and tumor endothelial cells express phosphatidylserine (PS), a highly immunosuppressive membrane… 
2016
2016
Abstract P4-04-03: Targeting of phosphatidylserine by monoclonal antibodies augments the activity of immune checkpoint inhibitor PD-1/PD-L1 therapy in murine breast tumors
Phosphatidylserine (PS) is a phospholipid that typically resides in the inner leaflet of the plasma membrane in many types of… 
2016
2016
Docetaxel and bavituximab in nonsquamous NSCLC 1 Docetaxel Plus Bavituximab in Previously Treated , Advanced Nonsquamous Non – small-cell Lung Cancer
Background: Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed immune response… 
2016
2016
Abstract B116: Antibody-mediated blockade of phosphatidylserine combined with intense radiation improves survival and tumor eradication in rat models of non-small cell lung cancer
Stereotactic body radiation therapy (SBRT) uses image guidance to deliver very high doses of radiation, in no more than 5… 
2015
2015
Abstract 274: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3Dex vivosystem of lung cancer
Bavituximab is a monoclonal antibody directed against the membrane phospholipid phosphatidylserine exposed on the outer leaflet… 
2013
2013
Bavituximab Shows Promise in Phase II NSCLC Trial, May Move to Phase III
Based on revised data from a troubled phase II trial of the new drug bavituximab, Peregrine Pharmaceuticals is aiming to move the… 
2010
2010
Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.
7589 Background: Bavituximab, a novel chimeric IgG1 monoclonal antibody which targets the membrane phospholipid… 
2010
2010
Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results.
1062 Background: Bavituximab, a chimeric IgG1 monoclonal antibody against the membrane phospholipid, phosphatidylserine complexed… 
2009
2009
Research Highlights
49 assemble a eubacterial genome from short DNA fragment reads without the use of a reference genome—a process referred to as de… 
2007
2007
Bavituximab shows potential in chronic hep C
  • 2007
  • Corpus ID: 195099611